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coefﬁcientAbstract Purpose: To investigate whether high-b-value diffusion weighted imaging (DWI) and
the apparent diffusion coefﬁcient (ADC) values can differentiate pancreatic cancer (PC), mass
forming focal pancreatitis (MFFP), and normal pancreas.
Patients and methods: Diffusion weighted MR imaging (b= 0 and 800 s/mm2) was performed in
21 patients with histopathologically-proven pancreatic cancer, 19 patients with mass forming focal
pancreatitis proven by histopathology and/or clinical follow up, and 21 normal control subjects.
The signal intensity on DWI was visually evaluated and the ADC values of the pancreatic masses,
the remaining pancreas, and the normal pancreas were measured and compared.
Results: On high-b-value (800 s/mm2) DW images, PC was slightly more hyperintense, relative to
the remaining pancreas, than MFFP. The mean ADC value for PC (1.22 ± 0.101 · 103 mm2/s)
was signiﬁcantly lower than the remaining pancreas (1.99 ± 0.206 · 103 mm2/s; P< 0.001),
MFFP (1.53 ± 0.122 · 103 mm2/s; P< 0.001), and the pancreatic gland in the control group
(1.79 ± 0.061 · 103 mm2/s; P< 0.001). There was also a signiﬁcant difference between the mean
ADC values of MFFP and the remaining pancreas (1.53 ± 0.122 vs 1.89 ± 0.169 · 103 mm2/s;
P< 0.001).
Conclusion: Differences on DWI and ADC measurements help to differentiate pancreatic cancer,
mass forming focal pancreatitis, and normal pancreas.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
The differentiation between pancreatic cancer and mass form-
ing focal pancreatitis is important because their prognosis and
management are quite different (1–3). The overlap in the clin-
ical presentations and the imaging ﬁndings between these two
different entities may render the differentiation difﬁcult. Both
PC and MFFP may present with similar symptoms, as
688 M.A. El-Shinnawy et al.abdominal pain, weight loss, and pancreatic insufﬁciency (1,4).
Differentiation between PC and MFFP is a diagnostic chal-
lenge in clinical practice due to the facts that PC frequently re-
sults in pancreatitis, and chronic pancreatitis also carries an
increased risk of developing PC (5).
Standard cross-sectional imaging techniques including
computed tomography (CT) and magnetic resonance imaging
(MRI) may be inconclusive to distinguish PC from MFFP
(6,7). MFFP, which is a benign inﬂammatory disease, may mi-
mic the desmoplastic nature of PC due to the associated ﬁbro-
sis, presenting with similar imaging features including the
presence of a focal poorly enhanced mass with pancreatic
and biliary ductal abnormalities on dynamic CT and MRI
(8). Additionally, serial contrast-enhanced studies may not
be obtained in patients with renal disease because of the risk
of contrast-induced nephrotoxicity with CT and nephrogenicFig. 1 A 59-year-old male patient with adenocarcinoma of the body o
phase (a) shows the hypointense mass in the body of the pancreas. Di
hyperintense well demarcated mass of pancreatic adenocarcinoma (w
signal of associated pancreatitis, compared to the homogenous panc
1.07 · 103 mm2/s for the PC and 2.12 · 103 mm2/s for the associated
heavy T2 weighted MRI (f), sequelae of chronic pancreatitis.systemic ﬁbrosis with MRI (9,10). Percutaneous biopsy and
ﬁne-needle aspiration are reliable diagnostic tools for pancre-
atic tumors but carry the risks of pancreatic juice leakage
and tumor seeding, and may be inconclusive in cases of inaccu-
rate sampling (11). New developments in modern imaging
modalities, including CT and MRI have greatly improved
the diagnostic performance for pancreatic diseases; however,
the overall rate of incorrect diagnosis in differentiating be-
tween PC and MFFP is still up to 25% (4,12).
Diffusion-weighted imaging is a unique MRI method that
provides information about the microstructural characteristics
of biological tissues by detecting the thermally induced ran-
dom molecular motion of water molecules, and generates rep-
resentative ADC values that represent the microcirculation of
blood (perfusion) as well as molecular diffusion of water
(13,14).f the pancreas. Contrast enhanced T1 weighted MRI in the arterial
ffusion weighted images (b & c) with b= 800 s/mm2 show a very
hite arrow in b) surrounded by a less hyperintense heterogenous
reatic tail (c & e). ADC values on the ADC maps (d & e) are
pancreatitis. Note the irregularly dilated beaded pancreatic duct on
Can high-b-value diffusion weighted imaging differentiate between pancreatic cancer 689The purpose of this study is to evaluate the diagnostic util-
ity of pancreatic DWI and determine whether high-b-value
DWI and ADC quantiﬁcation can differentiate between pan-
creatic cancer, mass forming focal pancreatitis, and normal
pancreatic parenchyma.
2. Materials and methods
2.1. Patients
During an 18-month period from September 2012 to March
2013, 40 patients suspected of having solid pancreatic masses
were prospectively examined by DWI after obtaining an in-
formed consent. The pancreatic cancer group was composed
of 21 patients (13 males, 8 females, age range 45–81 years,
mean 65 years) with histopathologic proof of PC through ﬁne
needle aspiration in 4 patients and Whipple procedure in 17
patients. The mass forming focal pancreatitis group consisted
of 19 patients (15 males, 4 females, age range 41–76 years,Fig. 2 A 53-year-old female patient with adenocarcinoma of the unci
in the arterial phase (a) reveals a bulky poorly enhancing uncinate pr
weighted image with b= 800 s/mm2 (b), clearly depicted on the inverte
ADC value of 1.23 · 103 mm2/s. Homogenous pancreatic body and ta
(f) with an ADC value of 1.93 · 103 mm2/s.mean 56 years) in whom the diagnosis of MFFP was deter-
mined by histopathology and/or by clinical follow up. MFFP
was conﬁrmed by histopathology in 6 patients and follow up
imaging of these patients was performed at least 6 months
after the histopathology-proven diagnosis. Thirteen patients
had a clinically established diagnosis of MFFP without histo-
pathologic conﬁrmation and were concluded with the absence
of malignancy based on repeat imaging and clinical follow-up
between 6–12 months after the initial presentation. On follow
up examinations, the size of the pancreatic mass and degree
of ductal obstruction, if present, were evaluated, as well as
search for inﬁltration of adjacent organs, metastatic deposits
and lymphadenopathies.
All patients underwent the same imaging protocol for the
diffusion-weighted imaging, and the time interval between
MRI and surgery and/or histopathologic proof was less than
four weeks.
Twenty-one patients who were referred to our MRI unit for
imaging of the liver were also enrolled in our study as a normalnate process of the pancreas. Contrast enhanced T1 weighted MRI
ocess (white arrows) showing intense hyperintensity on diffusion
d black-and-white image contrast (c) and the ADC map (d) with an
il are demonstrated on diffusion weighted image (e) and ADC map
690 M.A. El-Shinnawy et al.control group. They were 17 males and 4 females aged 43–
75 years (mean 58 years). None of these patients had a history
of pancreatic disease and all had normal serum amylase and
serum lipase levels. DWI of the pancreas was performed in
addition to the routine liver MR imaging after obtaining in-
formed consent.2.2. MR imaging protocol
All patients underwent MR imaging of the upper abdomen per-
formed on a 1.5T MR scanner (Achieva; Philips Medical Sys-
tems, Bothell, WA, USA) using a Torso radiofrequency coil.
Routine pancreatic MR imaging protocol consisted of: a respira-
tory triggered T1-weighted spoiled gradient-echo (SGE) in dual
phase, T1-weighted fat-saturated 2D SGE, and T2-weighted fast
spin-echo sequence with and without fat saturation.
Serial contrast-enhanced images were acquired at 25 s (arte-
rial phase), one minute (portal venous phase), 2 min (venousFig. 3 A 63-year-old female patient with pancreatic head adenoca
(curved white arrow) in the medial aspect of the pancreatic head on T2
diffusion weighted MRI (b), with an ADC value of 1.12 · 103 mm2/s o
in a & b). Homogenous signal intensity of the remaining pancreatic bod
value of 1.99 · 103 mm2/s on the ADC map (e). Note the hyperintense
displaying diffusion restriction in DWI (b), which proved to be a metphase), and 4 min (delayed phase) of contrast administration
using a breath-hold T1-weighted fat- saturated 2D SGE pulse
sequence. Gd-DTPA (Magnevist; Bayer, Wayne, NJ, USA)
was administered in a dose of 0.1 mmol/kg of body weight
as a bolus injection at 2 mL/s using a power injector (Medrad,
Indianola, PA, USA).
DW imaging was performed using a respiratory – triggered
echo-planar imaging (EPI) technique with TR/TE = 2745 ms/
68 ms; matrix size = 140 · 108; FOV = 250–420 mm; num-
ber of excitations = 6, EPI factor = 57; a SENSE factor of
2, slice thickness = 5 mm, slice gap = 1 mm, and acquisition
time = 3–4 min. The b-values were set at 0 and 800 s/mm2.
ADC images were calculated from individually acquired
images with a diffusion gradient applied along the x, y, and
z orthogonal axes.
The decision to obtain DWI using a large gradient factor,
b= 800 s/mm2, was based on a method to separate the effects
of diffusion and ﬂowing spins, which brieﬂy proposes that
when a pair of DW images is obtained with a gradient factorrcinoma. The pancreatic head shows a faintly hyperintense mass
weighted MRI (a), appearing well demarcated very hyperintense on
n the ADC map (c). CBD stent is seen in situ (notched white arrow
y and tail is seen on the diffusion weighted MRI (d), with an ADC
rounded signal (straight white arrow) in the vertebral body in (a),
astatic deposit on further evaluation by isotope bone scan.
Can high-b-value diffusion weighted imaging differentiate between pancreatic cancer 691of 0 s/mm2 (b0) and a certain gradient factor (b1), ADC can be
calculated as S1 = S0 · exp (b1 · ADC), where S0 and S1 are
the signal intensities of the images obtained with gradient fac-
tors of b0 and b1 (15). Signal attenuation on DW images at b1
is inﬂuenced by both diffusion and perfusion, and as a result,
ADC calculated from this pair of DW images also reﬂects the
effect of both. Because the signal attenuation of the perfusion
component on DW images occurs predominantly in a range of
low gradient factors, then DW images obtained with strong en-
ough gradient factors can eliminate all signals from the perfu-
sion component, and the DW images obtained can be regarded
only as a result of diffusion (16).
2.3. Image analysis
All images were loaded to a workstation (HPZR 24 W; Philips
Medical Systems) and consensus reading was performed by
two experienced radiologists, each with more than 5 years ofFig. 4 A 62-year-old male patient with mass-forming focal panc
hypointense mass (curved white arrow) on contrast enhanced T1 wei
weighted fat suppressed image (b) with faint heterogenous hyperintensit
image contrast (d), and an ADC value of 1.62 · 103 mm2/s. The rem
restriction on diffusion weighted MRI (e) with an ADC value of
hydronephrotic kidney.experience in abdominal radiology. Pancreatic masses were ini-
tially localized on T1- weighted fat-saturated pre-contrast and
serial contrast-enhanced images and visually correlated with
DWI of b= 0 and b= 800 s/mm2. DWI was provided with
black-and-white inversion display to facilitate lesion detection.
ADC values of the pancreatic lesion were measured in all pa-
tients using an operator-deﬁned circular region of interest
(ROI), which was lesion-size-dependent and no less than
100 mm2. During measurement, areas of cysts, pancreatic ves-
sels, the pancreatic duct and the common bile duct were ex-
cluded and left out of the ROI. The ADC values, the
maximum size of the mass, and ADC values of the remaining
gland were measured in patients with PC and MFFP. For each
patient in the control group, the mean value from the head,
body, and tail measurements was calculated with a standard-
sized ROI = 100 mm2. ADC values were calculated using
the software provided by the MR scanner manufacturer (Dif-
fusion Calculation: Philips Medical Systems).reatitis. The pancreatic head shows an ill-deﬁned heterogously
ghted MRI in the arterial phase (a), faintly hyper-intense on T2-
y on diffusion weighted image (c) and the inverted black-and-white
aining pancreatic tail (straight white arrow) shows no diffusion
1.89 · 103 mm2/s on the ADC map (f). Note of left chronic
692 M.A. El-Shinnawy et al.2.4. Statistical analysis
The Student’s t-test was used for comparison between two inde-
pendent mean groups for parametric data to determine the sig-
niﬁcance between the ADC values of the pancreatic gland in the
control group, MFFP, PC and the remaining pancreas. All val-
ues were expressed as mean ± SD for quantitative parametric
measures. The probability of error (P value) of <0.05 was con-
sidered statistically signiﬁcant, while at 0.01 and 0.001 were
highly signiﬁcant. IBM SPSS statistics (V. 21.0, IBM Corp.,
USA, 2012) was used for data analysis.
3. Results
Of the 21 pancreatic cancer patients, 15 tumors were located in
the pancreatic head, 5 were in the pancreatic body, and 1 in the
pancreatic tail. The pancreatic cancer masses were revealed as
well-deﬁned and poorly enhanced focal lesions on the contrast-
enhanced T1-weighted MR images (Figs. 1-3). The maximum
diameter of PC ranged from 1.6–5.2 cm (mean 3.1 cm). Mass
forming focal pancreatitis was located in the pancreatic head
in 16 patients and in the body in 3 patients. The maximumFig. 5 A 74-year-old male patient with mass-forming focal pancreat
(a) shows an illdeﬁned hyperintense pancreatic head mass (curved wh
the portal-venous phase (b). Diffusion weighted images show a slightly
pancreas (straight white arrow) in (d), with ADC values on the ADC
compared to 1.78 · 103 mm2/s for the remaining pancreas. Bilateraldiameter of the MFFP ranged from 2.4–5.8 cm (mean
3.9 cm), and were revealed as ill-deﬁned hypo-intense lesions
on contrast-enhanced MR images (Figs. 4 and 5).
On visual analysis of high b value (b= 800 s/mm2) DWI,
both PC and MFFP were revealed as hyperintense focal le-
sions, with PC showing higher signal intensities (Figs. 1 and
2). Pancreatic cancer masses appeared predominantly well
demarcated by hyperintense signal and slightly heterogeneous
pattern, while MFFP appeared predominantly illdeﬁned and
heterogenous (Figs. 4 and 5). The pancreatic gland in the con-
trol group revealed homogenous signal intensity throughout
the gland on b= 800 s/mm2 DW images and its corresponding
ADC map images (Fig. 6).
The mean ADC values of PC, MFFP, and normal pancreas
in the control group are shown in Table 1 and Fig. 7. The mean
ADC value of the normal pancreas (1.79 ± 0.061 · 103 mm2/
s) did not signiﬁcantly vary between the pancreatic head, body,
and tail. The mean ADC value of pancreatic cancer (1.22 ±
0.101 · 103 mm2/s) was signiﬁcantly lower than the remaining
pancreas (1.99 ± 0.206 · 103 mm2/s) (P< 0.001), mass form-
ing focal pancreatitis (1.53 ± 0.122 · 103 mm2/s) (P<
0.001), and the pancreatic gland in the control group (1.79 ±
0.061 · 103 mm2/s) (P< 0.001).itis of the pancreatic head. T2-weighted MRI with fat suppression
ite arrow) displaying poor heterogenous contrast enhancement on
hyperintense pancreatic head mass (c), compared to the remaining
maps (e & f) of 1.51 · 103 mm2/s for the pancreatic head mass,
simple cortical renal cysts are noted.
Fig. 6 A 54-year-old subject with normal pancreatic function tests. Contrast enhanced T1 weighted fat saturated MRI in the arterial
phase (a), and portal-venous phase (b) show uniform enhancement of the pancreatic parenchyma compatible with the normal gland.
Diffusion-weighted image (c) and ADC map (d) of the normal pancreas with mean ADC values of 1.76 x103 mm2/s.
Table 1 Mean ADC values for pancreatic cancer, mass
forming focal pancreatitis, and normal pancreas.
Pancreatic Disease n ADC values ± S.D*
Pancreatic cancer 21 1.22 ± 0.101 (range 1.07–1.37)
MFFP 19 1.53 ± 0.122 (range 1.37–1.69)
None 21 1.79 ± 0.061 (range 1.68–1.90)
ADC= apparent diffusion coefﬁcient.
MFFP= mass forming focal pancreatitis.
* Data are mean (x103 mm2/s) ± standard deviation.
Fig. 7 Boxplots of the apparent diffusion coefﬁcient (ADC)
values of the normal pancreas (control), mass forming focal
pancreatitis (MFFP), and pancreatic cancer (PC).
Can high-b-value diffusion weighted imaging differentiate between pancreatic cancer 693ThemeanADC value ofMFFP (1.53 ± 0.122 · 103 mm2/s)
was lower than the control group (1.79 ± 0.061 · 103 mm2/s)
and there was a signiﬁcant difference between the mean ADC
values of MFFP and the remaining pancreas (1.53 ± 0.122 vs.
1.89 ± 0.169 · 103 mm2/s; P< 0.001).
4. Discussion
Pancreatic cancer is the third most common malignancy of the
gastrointestinal tract. The main diagnostic imaging task in
pancreatic lesions is their detection and differentiation into
malignant and benign (e.g. inﬂammatory) entities as well as
to assess resectability of pancreatic cancer. Mass forming focal
pancreatitis can mimic pancreatic cancer and this may lead to
a difﬁcult preoperative differential diagnosis (17).
The recent development of MR systems with high-gradient
amplitude and parallel imaging technique have greatlyimproved the diagnostic performance of abdominal DW imag-
ing (18). On DWI, correct choice of the b-value determines the
assessment of cellular density and/or perfusion in the ROI, and
can be contaminated by T2 effect, because the DW sequence
itself has a certain T2 weight. High b-values have been used
to diminish the interference from the T2 and perfusion effects;
however, increasing the b-value can reduce the signal-to-noise
694 M.A. El-Shinnawy et al.ratio (SNR) (19,20). Respiratory triggering method was rec-
ommended by authors (18,21) in high b-value DWI of the pan-
creas to improve the SNR and improve the spatial resolution.
In our high b-value (800 s/mm2) DWI study, with the applica-
tion of parallel imaging to limit the susceptibility artifacts and
breath triggering technique to increase the SNR, a satisfying
image quality has been obtained, with an acceptable acquisi-
tion time.
Authors have proposed that DWI with a high b-value was
preferable for differentiating pancreatic mass lesions
(3,8,18,19,22,23). In our patient population, visual analysis
of DWI with a b-value of 800 s/mm2, revealed PC and MFFP
as hyperintense focal lesions, since both of these different enti-
ties have a large amount of ﬁbrous components (6). Our results
are well agreed with Huang et al. (1), who described that pan-
creatic carcinomas showed more hyperintense signal intensities
and were mostly well demarcated from the surrounding pan-
creas (Figs. 1–3), while MFFP mostly presented with ill-de-
ﬁned borders (Figs. 4 and 5). Similar studies reported that
PC showed a very high signal intensity (8,19,22,23), while oth-
ers reported that MFFP showed iso or a low signal intensity
compared to the remaining pancreas (6,8).
The ADC value measurement is more widely used for water
diffusion quantiﬁcation than DWI because it can wrinkle out
the T2 shine-through effect (19). Lee et al. (18) reported that
the ADC value derived from a higher b value DWI provides
a better sensitivity and speciﬁcity in discriminating PC from
MFFP than from a low b value DWI. As demonstrated previ-
ously in several studies (1,6,18,21–24) and conﬁrmed in our
study, the ADC values of pancreatic cancer were lower than
those of normal pancreas. The decreased ADC value in pan-
creatic malignancy is explained by the increased tumor cellu-
larity and characteristic desmoplastic ﬁbrotic stroma causing
restricted water diffusion, resulting in low ADC values (22).
Our results showed that the ADC values of pancreatic can-
cer were signiﬁcantly lower than that of the remaining pan-
creas, MFFP, and the normal pancreas in the control group,
and the ADC values of MFFP were also signiﬁcantly lower
than that of the remaining pancreas and the normal pancreas
in the control group. Our ﬁndings are consistent with Huang
et al. (1) and Matsuki et al. (22) who reported similar results.
The restricted diffusion and low ADC in MFFP could be ex-
plained by the extensive granulation tissue, inﬂammatory cells,
and ﬁbrosis (13). The difference in ADC values between PC
and MFFP might be attributed to the difference in their histo-
logical features, as highly ﬁbrotic pancreatic carcinoma con-
sists of more intense cellular density than MFFP, and
therefore present with an even lower ADC value (25).
The presence of inﬂammation surrounding the PC has been
reported, which may occur due to ductal obstruction, corre-
lated with an increase in water diffusion, and thus have in-
creased ADC values (26). This has been observed in our
study (Fig. 1), in agreement with other authors (6,22), as in-
creased ADC values of the remaining pancreas in PC com-
pared to the normal pancreas in the control group.
Variations in ADC values of pancreatic cancer exist accord-
ing to previous reports. This might depend partially on the
selection of b-values and the ﬁeld strength of the scanner
(27), and it might also be explained with the variable composi-
tion of PC with ﬁbrosis, increased cellularity and necrosis,
which may affect its imaging features. Necrosis is associatedwith increased ADC values due to increased motion of water
protons in the tissues (28).
In a study by Takeuchi et al. (8), the ADC in MFFP was
signiﬁcantly lower than that in PC and the authors attributed
this result to the rather small size of MFFP which might have
been affected by partial volume effect, resulting in false low
values.
A signiﬁcant overlap in ADC values for PC and MFFP has
been reported by Wiggermann et al. (29), with the consequent
problem of their differentiation, due to placement of a large
ROI covering the whole lesion including pancreatic necrosis.
Their results demonstrated signiﬁcantly higher ADC values
in PC and MFFP compared to the normal pancreas, with no
signiﬁcant difference in ADC values between PC and MFFP.
Huang et al. (1) reported a similar overlap in ADC values be-
tween PC and MFFP in some cases and similarly attributed it
to intratumoral necrosis, resulting in increased water diffusion.
Accordingly, from the various techniques that have been de-
scribed to measure ADC values of pancreatic lesions, we rec-
ommend to place the ROI on the solid component, excluding
necrotic areas, cysts, ducts and vessels, to avoid ADC value
overlap.
In conclusion, according to the results of our study, high
b-value DWI and ADC values can help differentiate pancreatic
cancer, mass forming focal pancreatitis, and normal pancreas,
however, studies with a larger number of patients are needed
to establish a possible cutoff value for malignancy.
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